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ABSTRACT 
Whether and when recovery beyond the need for transplant may occur in patients listed for 
decompensation remains unclear. This study aimed to investigate the characteristics of patients 
delisted following recompensation. Seventy-seven patients who were listed between 2005 and 2015 
for decompensation, but later delisted following recompensation were included. Alcohol-related liver 
disease (ALD) was the underlying etiology in the majority (n=47, 61%). Listing characteristics of these 
patients were compared with those of decompensated ALD patients who either underwent deceased 
donor liver transplantation or died on the waiting list. The model for end-stage liver disease (MELD) 
score <20 and serum albumin ≥32g/l at listing were the only independent predictors of 
recompensation/delisting in ALD. The probability of recompensation was 70% when both factors 
were present at listing. Interestingly, about a tenth of decompensated ALD patients who died on the 
waiting list (median duration on waiting list 11 months) and a quarter of decompensated ALD patients 
who underwent living donor liver transplantation (median duration on waiting list 2 months) also had 
both factors at listing. In conclusion, ALD seems to be the most favorable etiology for recompensation 
beyond the need for transplantation. Both MELD and serum albumin at listing independently predict 
recompensation/delisting in ALD. It seems advisable to implement a period of observation for ALD 
patients with both favorable factors, before embarking on living donor liver transplantation.  
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INTRODUCTION 
Development of hepatic decompensation, which marks the onset of end-stage liver disease, is an 
ominous milestone of chronic liver disease progression, irrespective of the etiology. It is defined as 
the manifestation of an index complication such as ascites, hepatic encephalopathy, variceal 
hemorrhage or hepatocellular dysfunction in a patient with cirrhosis (1, 2). 
 
Decompensation impairs patient survival (3, 4) and liver transplantation (LT) remains the only 
treatment option improving the dismal prognosis. Development of ascites is associated with a 1-year 
mortality of 15%, which increases to >60% when complicated by hyponatremia, hepatorenal 
syndrome and/or superimposed spontaneous bacterial peritonitis (5, 6). Similarly, both hepatic 
encephalopathy (7) and variceal bleeding (8) are associated with poor prognosis. However, 
improvement in hepatic function and recompensation is occasionally seen in day-to-day clinical 
practice, even in patients listed for LT. 
 
The availability of potent antiviral agents against hepatitis B and C has confirmed the potential for 
recompensation in selected patients, thus changing the paradigm of hepatic decompensation. The 
use of direct-acting antivirals in patients on transplant waiting list has shown significant clinical 
improvement leading to delisting (9-11). However, literature on recompensation of liver disease from 
other etiologies is sparse. 
 
This study aimed to determine the clinical characteristics of patients delisted following 
recompensation and to identify the clinical parameters at listing which were associated with 
recompensation on waiting list.  
 
5 
 
MATERIALS & METHODS 
Patient selection and data collection 
This is a retrospective analysis of prospectively collected data from a single, high volume liver 
transplant center. All adult patients who were wait-listed in the Toronto liver transplant program 
between January 2005 and December 2015 for decompensated chronic liver disease, but later 
delisted following recompensation were eligible for inclusion into the study cohort. Etiology-
matched patients who were listed during the same period for decompensation and either underwent 
deceased donor LT or died on waiting list were chosen as controls. Etiology-matched patients who 
were listed during the same period for decompensation and underwent living donor LT and therefore 
did not follow the ‘natural’ course on the waiting list served as a second control group. 
 
The following patients were excluded from the study: (a) patients with associated hepatocellular 
carcinoma, (b) patients listed for decompensation and later delisted for reasons other than 
recompensation, (c) patients listed for reasons other than decompensation such as recurrent 
cholangitis in primary sclerosing cholangitis and intractable pruritus in primary biliary cholangitis, (d) 
patients listed for acute liver failure, (e) patients listed for other reasons such as polycystic liver 
disease, amyloidosis, vascular liver disease (e.g. Budd-Chiari syndrome, sinusoidal obstruction 
syndrome), inborn errors of metabolism (e.g. glycogen storage diseases, Tyrosinemia, Citrullinemia, 
Maple Syrup Urine Disease, and Hyperoxaluria), and (f) patients listed for re-transplantation or with 
a prior non-liver organ transplant including bone marrow transplantation.  
 
Demographic and clinical data were retrospectively extracted from the prospectively collected 
electronic transplant database (OTTR: Transplant Care Platform 6, OTTR Chronic Care Solutions, 
Omaha, NE). The original Model for End-stage Liver disease score (MELD(O)) (12, 13) and the recently 
updated, serum sodium incorporated Model for End-stage Liver Disease score (MELD; Organ 
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Procurement and Transplantation Network Policy 9.1, January 2016) were calculated at listing. The 
study was approved by the Toronto University Health Network Research Ethics Board (16–5178–BE). 
 
Listing criteria for decompensation and delisting criteria following recompensation 
The listing criteria of the Toronto liver transplant program are that of Ontario province. Patients are 
only considered for listing when all other therapeutic options have been exhausted and expected 5-
year survival (from non-liver-related co-morbidity) is ≥50%. Listing for hepatic decompensation is 
considered in patients with ascites or complications thereof such as hepatic hydrothorax and 
spontaneous bacterial peritonitis (resolved), jaundice, hepatic encephalopathy or portal hypertensive 
gastrointestinal bleed and a MELD score of ≥15. Patients with decompensation and MELD 11 – 14 are 
reviewed on a case-by-case basis and are listed only if the MELD score is deemed not reflective of 
their poor prognosis. Prior to the incorporation of MELD score in 2007, Child-Pugh B score ≥7 was 
used for listing of patients with decompensation. In addition, a minimum 6 months’ alcohol 
abstinence and specialist psychiatrist review to confirm the commitment to abstinence and to assess 
the risk of recidivism are mandatory for patients with alcohol-related liver disease (ALD).  
 
Recompensation was a clinical diagnosis. Absence of ascites/hepatic hydrothorax/peripheral edema 
despite the discontinuation of diuretics and the absence of hepatic encephalopathy without the need 
for prophylactic treatment along with an improvement in the MELD score to <15 in a patient who was 
initially placed on the waiting list for such features of decompensation was considered as 
recompensation. All patients who achieved recompensation were placed ‘on hold’ for at least 6 
months to confirm the durability of recompensation and were reviewed by at least two hepatologists 
prior to delisting. Delisting is defined as the permanent removal of a patient from the LT waiting list.  
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Endpoint 
The primary endpoint was to identify factors at listing, which were associated with delisting following 
recompensation. 
 
Data analysis and statistics 
An etiology-matched comparison was only undertaken if there were adequate numbers of patients 
in the study group. Data are shown as median (interquartile range) or number (percentage) unless 
otherwise stated. All statistical analyses were performed using either GraphPad prism 5 (San Diego, 
CA) or SPSS for Windows v20. A p-value of <0.05 was considered statistically significant. Clinical 
parameters at listing were analyzed for association with the outcome (delisting following 
recompensation versus transplantation or death on waiting list) using the Mann–Whitney U test or 1-
way ANOVA (Kruskal-Wallis test) as appropriate. A multivariable logistic regression model 
incorporating variables with a p value of <0.10 on univariate testing was used to determine 
independent associations with delisting following recompensation. 
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RESULTS 
Clinical characteristics of all patients delisted following recompensation (all etiologies) 
A total of 935 patients were listed for decompensation alone and underwent LT, died on the waiting 
list, or delisted following recompensation during the 10-year study period – ALD (n=284, 30%), 
hepatitis C (n=239, 26%), and non-alcohol-related fatty liver disease (n=115, 12%) were the three 
most common etiologies, followed by primary sclerosing cholangitis (n=71, 8%), hepatitis B (n=55, 
6%), primary biliary cholangitis (n=47, 5%), cryptogenic cirrhosis (n=45, 5%), autoimmune hepatitis 
(n=38, 4%), and others (n=41, 4%).  
 
Of the 935 patients, 77 patients were delisted following recompensation and formed the study group. 
The median age at listing was 54 years (IQR 47 – 59); the majority were males (n=49, 64%) and the 
median BMI at listing was 26.2 (IQR 24.5 – 29.3). The median MELD(O) and MELD scores were 14 (IQR 
13 – 16) and 15 (IQR 13 – 19), respectively. The median duration on the waiting list was 18 months (12 
– 29). In the vast majority (n=64, 83%) recompensation was spontaneous; in the rest, potential 
contributing factors for recompensation included insertion of a transjugular intrahepatic 
portosystemic shunt (n=4, 5%) and initiation of specific treatment of the underlying etiology (n=9, 
12%). 
 
ALD was the most common etiology (n=47, 61%) in the study cohort; the rest of etiologies only 
accounted for a small number of patients. Etiology-specific clinical characteristics and potential 
reasons for recompensation are summarized in Table 1. All 77 patients had clinical manifestation of 
primary hepatocellular dysfunction in the form of ascites with/without hepatic hydrothorax and 
peripheral edema at listing. Over half these patients (n=40, 52%) had at least one episode of overt 
hepatic encephalopathy, nearly a quarter of patients (n=18, 23%) had a history of gastrointestinal 
bleeding attributed to portal hypertension, and 13% (n=10) had a history of confirmed spontaneous 
bacterial peritonitis.  
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Only 4 (5%) patients (2 with ALD, 1 with hepatitis C, and 1 with autoimmune hepatitis) were re-
referred for LT evaluation after delisting, with a median interval of 4 years (IQR 3 – 6). Of the 4 
patients, 2 were accepted for LT and are currently on the waiting list (one with hepatitis C and the 
other with autoimmune hepatitis); the other 2, both with ALD and previous transjugular intrahepatic 
portosystemic shunt insertion, were felt not to have favorable risk/benefit balance for LT due to 
advanced age and medical comorbidities, and were not accepted on the waiting list. 
 
 
Comparison of patients delisted following recompensation and those who underwent deceased 
donor LT / died on waiting list (only ALD) 
ALD accounted for nearly two thirds of patients who were delisted following recompensation; the 
rest of the etiologies were not adequately represented in number. Therefore, further analyses were 
undertaken only in those who were listed for decompensated ALD. 
 
A comparison between the patients who were delisted following recompensation (n=47) and those 
who underwent deceased donor LT or died on waiting list (n=194) is summarized in Table 2.1. Age, 
BMI, and duration of abstinence at listing were similar between the two groups. All laboratory 
parameters at listing except serum creatinine were significantly worse in those who underwent 
deceased donor LT or died on the waiting list. 
 
On univariate analysis (Table 2.2) female sex, bilirubin, INR, creatinine, serum sodium, MELD(O), 
MELD, albumin, and platelets at listing were predictive of delisting following recompensation. Before 
proceeding with multivariate analysis, a receiver operating characteristic (ROC) curve analysis was 
performed to compare the predictability of MELD and its components (Figure 1). MELD at listing was 
a better predictor (AUROC 0.853) of delisting following recompensation than MELD(O), bilirubin, INR, 
10 
 
creatinine, and serum sodium. Therefore, only MELD along with sex, BMI, albumin, and platelets at 
listing were taken forward for multivariate analysis. 
 
On multivariate analysis (Table 2.2), MELD and albumin at listing were the only independent 
predictors of delisting following recompensation. Using Youden-Index (J), MELD <20 at listing 
(sensitivity 79%, specificity 76%) and albumin ≥32 g/l at listing (sensitivity 68%, specificity 67%) were 
found to be the optimal cutoffs in predicting delisting following recompensation in ALD. 
 
The probability of being delisted following recompensation (positive predictive value, PPV) with 
MELD <20 at listing was 0.45 and with albumin ≥32 g/l at listing was 0.33. Combing both factors 
improved the PPV to 0.71. The cumulative incidence of being delisted following recompensation of 
patients with MELD <20 and albumin ≥32 g/l is shown in figure 2. On the other hand, the negative 
predictive value (NPV) for delisting following recompensation of MELD <20, albumin ≥32 g/l, and 
both combined were 0.94, 0.90, and 0.89, respectively. 
 
Interestingly, 8 of the 72 (11%) patients who died on the waiting list had both MELD <20 and albumin 
≥32 g/l at listing. These patients spent a median of 11 months (IQR 6 – 18) on the waiting list compared 
to 23 months (IQR 14 – 33) spent by those who were delisted following recompensation. 
 
 
Comparison of patients delisted following recompensation and those who underwent living 
donor LT (only ALD) 
A comparison between the patients with decompensated ALD who were delisted following 
recompensation (n=47) and those who underwent living donor LT (n=43) is summarized in Table 3. 
MELD(O), MELD, serum sodium at listing, and duration on waiting list were significantly different 
11 
 
between the two groups. Difference in bilirubin (p=0.053), INR (p=0.08), creatinine (p=0.07), and 
albumin (p=0.0503) approached, but did not reach statistical significance.  
 
The difference in clinical parameters between the patients delisted following recompensation and 
those that underwent living donor LT (Table 3) were less marked compared to the difference between 
those delisted following recompensation and those that underwent deceased donor LT / died on 
waiting list (Table 2.1). Therefore, further analysis was undertaken to explore the possibility that at 
least some of the patients who underwent living donor LT may have had the chance to recompensate 
and be delisted, if the ‘natural’ course of the disease had not been intervened upon with living donor 
LT. 
 
Eleven of the 43 (26%) patients who underwent living donor LT were found to have both MELD <20 
and albumin ≥32 g/l at listing. These patients spent a median of 2 months (IQR 1 – 4) before 
undergoing LT. 
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DISCUSSION 
This retrospective, single center study describes the listing characteristics of patients with 
decompensated chronic liver disease of all etiologies, who recompensated on the waiting list and 
were delisted as transplantation no longer carried a survival benefit. Potential predictors of delisting 
following recompensation was assessed only for ALD; other etiologies were present in too small 
numbers in the recompensation group to allow a meaningful statistical analysis. In patients with 
decompensated ALD, MELD <20 and serum albumin ≥32 g/l at listing were independently associated 
with being delisted following recompensation. The presence of both factors at listing improved the 
probability of recompensation and delisting to >70%. 
 
Improvement in fibrosis and portal hypertension has been demonstrated in patients with hepatitis C 
compensated cirrhosis following successful antiviral treatment (14-16). Disease regression has also 
been documented in patients with hepatitis B compensated cirrhosis following antiviral therapy (17, 
18) and nonalcoholic steatohepatitis compensated cirrhosis following bariatric surgery (19). Studies 
from as early as a decade ago also demonstrated significant improvements in hepatic function and 
Child-Pugh scores in patients with decompensated hepatitis B cirrhosis following antiviral treatment 
(20-23); thus accentuate the potential for reversibility in both compensated and decompensated 
cirrhosis, which were once thought to be irreversible. However, it was not until the availability of 
potent, direct acting antivirals for hepatitis C that it became apparent that recompensation can occur 
to such a robust degree that patients no longer require transplantation. A recent multicenter 
European study showed recompensation with antiviral therapy leading to delisting of patients who 
were initially listed for decompensated hepatitis C (11). In addition, both MELD (at listing and 
improvement with antiviral treatment) and serum albumin (improvement with antiviral treatment) 
were predictive of recompensation following successful antiviral therapy (11).  
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The role of MELD as a predictor of recompensation in patients on the transplant waiting list is strongly 
supported by both, the European (11) and the current study. While lower MELD scores at 
baseline/listing increase the probability of recompensation, higher MELD scores seem to have a 
strong negative predictive role in patients with decompensated hepatitis C cirrhosis undergoing 
antiviral treatment (11) and waitlisted patients with decompensated ALD. This seems to suggest that 
the reversibility of liver damage upon cessation of injury depends on the severity of the liver disease, 
i.e. beyond a critical point, decompensation may no longer reverse to a clinically relevant degree even 
when the damaging insult no longer exists. Moreover, this ‘point of no return’ seems to be surprisingly 
similar for hepatitis C related liver disease and ALD. Which factor/s determine this critical point of no 
return has yet to be identified, and is beyond the scope of this discussion. 
 
Allocation of deceased donor grafts to patients depends on the regional waiting list and organ 
availability. In our transplant program, deceased donor grafts are only offered to patients with MELD 
of 25 – 30 or higher due to the scarce resource of donated organs. This prolongs waiting time during 
which patients’ clinical condition deteriorates substantially with increased waiting list mortality. 
Therefore, living donor LT is offered to all patients at their initial encounter with the service and this 
option is discussed and encouraged thereafter while they are on the waiting list. Living donor LT has 
a survival benefit comparable to that of deceased donor LT (24); even in the very sick (25, 26). In 
addition, the patient survival is significantly better with living donor LT compared to deceased donor 
LT, when measured from the time of listing (27, 28). However, living donor LT is not without its risks 
and complications not only to the recipient but also to the donor, and therefore should not be taken 
lightly. One quarter of patients who underwent living donor LT in our study fulfilled both criteria for 
potential recompensation (i.e. MELD <20 and albumin ≥32 g/l at listing), thus raising the question as 
to whether these patients were transplanted prematurely. Such a conclusion may be an 
oversimplification as 11% of patients who died on the waiting list also fulfilled these criteria at listing. 
Therefore, rather than deny the option of living donor LT to those who fulfill both criteria of potential 
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recompensation, a reasonable approach might be to institute a ‘period of observation’ on the waiting 
list to determine whether or not the clinical condition improves. Based on the duration on the waiting 
list of those who died despite fulfilling the predictive criteria (median 11 months; IQR 6 – 18), we 
propose that this ‘period of observation’ should be not more than 6 months from listing irrespective 
of the duration of abstinence prior to listing. 
 
As controversial as it may be, similar to most transplant centers, only those with at least 6 months of 
alcohol abstinence (‘6-month abstinence rule’) are considered for listing/transplantation. 
Interestingly and against expectations, alcohol abstinence beyond 6 months did not impact 
recompensation in this study. Whether this is because the beneficial effect of alcohol abstinence on 
recompensation is only evident within the first 6 months of abstinence or whether recompensation 
is dependent only on alcohol abstinence itself and not the duration of abstinence is not known. 
 
Interestingly, improvement of hepatic function allowing delisting was also evident in a small number 
of patients with etiologies such as hepatitis C, non-alcohol-related fatty liver disease, and cryptogenic 
cirrhosis, which are not known to result in spontaneous recompensation. This raises the question as 
to whether there were additional etiologies in these patients that were not reported/identified. 
Deliberate underestimation of self-reported alcohol consumption is widespread and well 
documented (29, 30). Whether some of these patients under-reported the amount of alcohol 
consumed and later stopped it upon listing which led to recompensation is not known. Further, due 
to the lack of literature on hepatic recompensation, it is not known whether true spontaneous 
recompensation does occur in a small number of patients in the above etiologies. 
 
The study has several strengths and limitations. The use of listing characteristics in the analysis (as 
opposed to progressive/dynamic changes in clinical parameters) makes the findings reflect 
prospective decision-making in a day-to-day clinical practice. On the other hand, this being a single 
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center study and having included limited numbers of patients in etiologies other than ALD prohibits 
further analysis for other causes of liver disease. Moreover, due to the retrospective design, the 
unavailability of data of factors which may have impacted recompensation such muscle 
mass/sarcopenia and alcohol-related characteristics such as lifetime total amount and type of 
alcoholic beverage, the duration of abuse and patterns of drinking could not be included in the 
analysis. Further, due to the ‘6-month abstinence rule’ those who recompensated during the first 6 
months of abstinence are not included in this analysis, potentially underestimating the actual 
proportion of recompensation. 
 
In conclusion, ALD seems to have a greater potential for recompensation especially in those with 
early stage decompensation. The severity of liver disease (MELD <20 and serum albumin ≥32 g/l) at 
the time of listing remains the only relevant predictor of recompensation. Interestingly, the duration 
of alcohol abstinence (beyond 6 months) seems to have no impact on recompensation. It may be 
advisable to implement a period of observation on the waiting list for those with early 
decompensated ALD to determine the course of progression before embarking on transplantation, 
especially in living donor LT candidates.  
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TABLES 
 
Table 1: Summary of all patients delisted following improvement of liver function and recompensation following listing for liver transplantation (n=77). 
 
Etiology of 
liver disease 
Number (%) of 
patients 
Likely reason/s for recompensation 
Laboratory characteristics at listing 
median (IQR) 
Duration on waiting 
list (months) 
Re-referrals 
ALD 47 (61%) 
TIPS insertion (n=3) 
Spontaneous (n=44) 
Bilirubin 38 (24 – 56); INR 1.40 (1.30 – 1.56) 
Creatinine 86 (70 – 108); Sodium 136 (134 – 138) 
Albumin 34 (30 – 36); Platelets 125 (95 – 165) 
19 (14 – 30) 2 
HCV 
12 (16%) 
[9 HCV RNA +ve] 
Successful antiviral treatment (n=4) 
TIPS insertion (n=1) 
Spontaneous (n=7) 
Bilirubin 43 (33 – 51); INR 1.49 (1.38 – 1.56) 
Creatinine 76 (53 – 94); Sodium 137 (136 – 140) 
Albumin 29 (29 – 33); Platelets 86 (60 – 119) 
20 (12 – 24) 1 
ALD/HCV 
4 (5%) 
[3 HCV RNA +ve] 
Spontaneous (n=4) 
Bilirubin 37 (31 – 42); INR 1.50 (1.44 – 1.51) 
Creatinine 89 (81 – 93); Sodium 138 (135 – 141) 
Albumin 30 (28 – 32); Platelets 83 (69 – 118) 
33 (24 – 37) none 
AIH 4 (5%) 
Initiation of Azathioprine treatment (n=2) 
Spontaneous (n=2) 
Bilirubin 46 (34 – 88); INR 1.46 (1.24 - 1.65) 
Creatinine 70 (66 – 77); Sodium 133 (129 – 136) 
Albumin 26 (26 – 27); Platelets 98 (71 – 130) 
11 (9 – 25) 1 
HBV 3 (4%) Initiation of antiviral treatment (n=3) 
Bilirubin 58 (38 – 81); INR 1.35 (1.28 – 1.39) 
Creatinine 111 (92 – 114); Sodium 141 (139 – 142) 
Albumin 32 (28 – 37); Platelets 152 (98 – 172) 
16 (15 – 17) none 
NASH 3 (4%) Spontaneous (n=3) 
Bilirubin 28 (26 – 45); INR 1.46 (1.42 – 1.48) 
Creatinine 86 (74 – 100); Sodium 136 (135 – 138) 
Albumin 32 (32 – 33); Platelets 148 (106 – 185) 
26 (18 – 39) none 
Sarcoidosis 2 (3%) Spontaneous (n=2) 
Bilirubin 25*; INR 1.25* 
Creatinine 113*; Sodium 138* 
Albumin 35*; Platelets 86* 
11* none 
PSC 1 (1%) Spontaneous (n=1) 
Bilirubin 65†; INR 1.37†; 
Creatinine 62†; Sodium 137† 
Albumin 36†; Platelets 81† 
16† none 
Cryptogenic 1 (1%) Spontaneous (n=1) 
Bilirubin 10†; INR 1.32† 
Creatinine 74†; Sodium 123† 
Albumin 22†; Platelets 225† 
40† none 
 
Abbreviations: AIH autoimmune liver disease; ALD alcohol-related liver disease; HBV hepatitis B related liver disease; HCV hepatitis C related liver disease; INR international normalized ratio; 
NASH non-alcohol-related steatohepatitis; PSC primary sclerosing cholangitis; TIPS transjugular intrahepatic portosystemic shunt. *average and †actual values 
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Table 2.1: Comparison between patients delisted following recompensation (n=47) and those who 
underwent deceased donor transplantation (DDLT) or died on the waiting list (n=194) after being 
listed for decompensation of ALD. 
 
 
Abbreviations: BMI body mass index; DDLT deceased donor liver transplantation; INR international normalized ratio; 
MELD model for end-stage liver disease. Of the 194 patients, 122 patients underwent DDLT and 72 died on the waiting list. 
A p value <0.05 in indicated in bold. 
 
 
Table 2.2: Predictors of recompensation – univariate and multivariate logistic regression. 
 
 
Abbreviations: BMI body mass index; INR international normalized ratio; MELD model for end-stage liver disease. A p value 
<0.05 in indicated in bold. MELD score and its components were included in the univariate analysis. Having shown that 
MELD is a better predictor of recompensation that its components (figure 1), only the MELD score was included in the 
multivariate analysis. * indicates the parameters which were included in the multivariate analysis. 
 
 
 
Recompensation (n=47) DDLT or Death (n=194) 
p-value 
median (IQR) / number (%) median (IQR) / number (%) 
Age at listing (years) 55 (50 – 59) 57 (51 – 61) 0.15 
Male sex 30 (64%) 158 (81%) 0.009 
BMI at listing (kg/m2) 26.2 (24.5 – 28.2) 27.7 (23.8 – 31.0) 0.08 
Duration on waiting list (months) 19 (14 – 30) 3 (1 – 9) <0.0001 
Duration of abstinence at listing (months) 12 (10 – 16) 12 (10 – 21) 0.22 
Bilirubin at listing (µmol/l) 38 (24 – 56) 83 (58 – 196) <0.0001 
INR at listing 1.40 (1.30 – 1.56) 1.90 (1.58 – 2.71) <0.0001 
Creatinine at listing (µmol/l) 86 (70 – 108) 113 (71 – 164) 0.06 
MELD(O) score at listing 14 (12 – 16) 23 (19 – 30) <0.0001 
Sodium at listing (mmol/l) 136 (134 – 138) 134 (130 – 137) 0.0005 
MELD score at listing 15 (12 – 19) 24 (20 – 29) <0.0001 
Albumin at listing (g/l) 34 (30 – 36) 30 (26 – 34) <0.0001 
Platelets at listing (x 109/l) 125 (95 – 165) 75 (53 – 114) <0.0001 
 
Univariate analysis Multivariate analysis 
OR (95% CI) p value OR (95% CI) p value 
Age at listing 0.97 (0.93 – 1.01) 0.13   
Male sex* 0.40 (0.20 – 0.81) 0.01 0.43 (0.17 – 1.06) 0.07 
BMI at listing* 0.94 (0.88 – 1.00) 0.07 1.01 (0.93 – 1.10) 0.81 
Duration of abstinence at listing 0.99 (0.98 – 1.01) 0.29   
Bilirubin at listing 0.97 (0.96 – 0.99) <0.001   
INR at listing 0.02 (0.00 – 0.10) <0.001   
Creatinine at listing 0.99 (0.98 – 1.00) 0.02   
MELD(O) score at listing 0.74 (0.66 – 0.82) <0.001   
Sodium at listing 1.11 (1.03 – 1.19) 0.004   
MELD score at listing* 0.78 (0.73 – 0.85) <0.001 0.81 (0.74 – 0.88) <0.001 
Albumin at listing* 1.13 (1.06 – 1.21) <0.001 1.11 (1.02 – 1.21) 0.02 
Platelets at listing* 1.01 (1.01 – 1.02) <0.001 1.00 (1.00 - 1.01) 0.20 
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Table 3: Comparison between those who were listed for decompensation of ALD and later delisted 
following recompensation (n=47) and those underwent living donor transplantation (n=43). 
 
 
Abbreviations: BMI body mass index; INR international normalized ratio; LDLT living donor liver transplantation; MELD 
model for end-stage liver disease. A p value <0.05 in indicated in bold. 
 
Recompensation (n=47) LDLT (n=43) 
p-value 
median (IQR) / number (%) median (IQR) / number (%) 
Age at listing (years) 55 (50 – 59) 57 (50 – 61) 0.18 
Male sex 30 (64%) 32 (74%) 0.28 
BMI at listing (kg/m2) 26.2 (24.5 – 28.2) 26.2 (22.9 – 29.6) 0.87 
Duration on waiting list (months) 19 (14 – 30) 3 (2 – 5) <0.0001 
Duration of abstinence at listing (months) 12 (10 – 16) 12 (10 – 15) 0.80 
Bilirubin at listing (µmol/l) 38 (24 – 56) 50 (27 – 68) 0.053 
INR at listing 1.40 (1.30 – 1.56) 1.51 (1.36 – 1.73) 0.08 
Creatinine at listing (µmol/l) 86 (70 – 108) 120 (90 – 150) 0.07 
MELD(O) score at listing 14 (12 – 16) 19 (15 – 22) 0.0008 
Sodium at listing (mmol/l) 136 (134 – 138) 131 (126 – 135) 0.0009 
MELD score at listing 15 (12 – 19) 20 (17 – 24) <0.0001 
Albumin at listing (g/l) 34 (30 – 36) 31 (28 – 34) 0.0503 
Platelets at listing (x 109/l) 125 (95 – 165) 93 (69 – 138) 0.35 
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FIGURE LEGENDS 
Figure 1 
Receiver operating characteristic (ROC) curve analysis of model for end-stage liver disease scores and 
their individual components in predicting delisting of patients following recompensation. 
Abbreviations: MELD(O), original model for end-stage liver disease score; MELD, recently updated 
(January 2016) model for end-stage liver disease score, which incorporates serum sodium in the 
calculation; INR, international normalized ratio. 
 
Figure 2 
The cumulative incidence of being delisted following recompensation of patients with both MELD 
<20 and albumin ≥32 g/l at listing. 
 
